Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Lynn M. Malec"'
Autor:
Robert F. Sidonio, Lynn M. Malec
Publikováno v:
Hematology/Oncology Clinics of North America. 35:1143-1155
The biology of factor IX deficiency leading to hemophilia B has important distinctions from factor VIII deficiency that leads to hemophilia A. In this article, the authors explore the unique biology of factor IX in hemostasis, including the importanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b2edf43196d3e412af5f9c2572e2e4d
https://doi.org/10.1016/j.hoc.2021.07.008
https://doi.org/10.1016/j.hoc.2021.07.008
Autor:
Robert F. Sidonio, Lynn M. Malec, Sarah A Hale, Imrran Halari, Jonathan C. Roberts, Abiola Oladapo
Publikováno v:
Haemophilia. 28:97-108
INTRODUCTION Von Willebrand disease (VWD) is the most common inherited bleeding disorder. The bleeding phenotype is variable, and some individuals have persistent symptoms post-diagnosis. AIM To characterize bleeding patterns in patients with VWD bef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57433e182aa142be10f769d67aeab9f7
https://doi.org/10.1111/hae.14448
https://doi.org/10.1111/hae.14448
Publikováno v:
Pediatrics in review. 41(7)
1. Amita Ghuman, MD* 2. Allison Close, MD† 3. Lynn Malec, MD, MSc‡ 1. *Department of Pediatrics and 2. †Division of Hematology/Oncology, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA 3. ‡Blood Research Institute, Blood Center of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f790cde56c0634603155a0099b29592
https://pubmed.ncbi.nlm.nih.gov/32611802
https://pubmed.ncbi.nlm.nih.gov/32611802
Publikováno v:
Haemophilia. 26
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bdb0474bf22c4a163ae0abb14c138dd
https://doi.org/10.1111/hae.13943
https://doi.org/10.1111/hae.13943
Autor:
Kelsey Johnson, Margaret V. Ragni, Michael Recht, Peter A. Kouides, Char Witmer, Dunlei Cheng, Julie Jaffray, Robert F. Sidonio, Stacy E. Croteau, Lynn M. Malec, Gilbert C. White, Kristina M. Haley
Publikováno v:
American journal of hematologyREFERENCES. 95(8)
With licensure of extended half-life (EHL) factor products and the changing landscape of available hemophilia products, patients and providers have options for less treatment-intense prophylaxis. The impact of these products in clinical practice to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65500f6aa10d15e9769b22d0d9cbaa01
https://pubmed.ncbi.nlm.nih.gov/32356313
https://pubmed.ncbi.nlm.nih.gov/32356313
Publikováno v:
Thrombosis research. 195
rFVIIIFc (Eloctate) is an extended-half-life recombinant factor VIII-Fc fusion protein that may promote factor VIII (FVIII) tolerance through Fc immunoregulatory properties. Yet, little is known regarding its immunogenicity in patients with hemophili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58645e5472e685ae273c9ce1e4204bde
https://pubmed.ncbi.nlm.nih.gov/32653601
https://pubmed.ncbi.nlm.nih.gov/32653601
Publikováno v:
Journal of Pediatric Gastroenterology & Nutrition. 66:972-975
Background Central venous access devices (CVADs) are essential for total parenteral nutrition administration in patients with short bowel syndrome (SBS). They are, however, fraught with complications including infection and venous thromboembolism (VT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38066c4e7abb11e2ff832162272a10fa
https://doi.org/10.1097/mpg.0000000000001836
https://doi.org/10.1097/mpg.0000000000001836
Autor:
Maissaa Janbain, Jacqueline N. Poston, Aric Parnes, Christopher E. Walsh, Lynn M. Malec, Craig M. Kessler, Kadhim Al-Banaa, Rebecca Kruse-Jarres, James F Wu, Annette von Drygalski
Publikováno v:
Blood. 138:496-496
Introduction Acquired hemophilia A (AHA) is a severe bleeding disorder due to autoantibodies against factor VIII (FVIII) with high morbidity/mortality from bleeding and complications from immunosuppression. Outcomes could improve with adequate hemost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bec53a79b900974ae8868538a33ddc2d
https://doi.org/10.1182/blood-2021-148040
https://doi.org/10.1182/blood-2021-148040
Autor:
Lynn M. Malec, Jean-Eric Tarride, Omotola O Olasupo, Amy D. Shapiro, Charles Nakar, Alfonso Iorio, Thushara Mathew, Craig Haddix, Davide Matino, Lawrence Mbuagbaw
Publikováno v:
Blood. 138:4990-4990
Background The development of antibodies (inhibitors) to clotting factors compromises the treatment of people with Hemophilia A (HA) and B (HB), and results in ineffective clotting-factor therapy, higher risk of complications, and need for bypassing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37a80627ccc829c7294dc94db69c09c4
https://doi.org/10.1182/blood-2021-147550
https://doi.org/10.1182/blood-2021-147550
Publikováno v:
Blood. 138:4242-4242
Background: Clinical researchers affiliated with the American Thrombosis and Hemostasis Network (ATHN) conduct multi-institutional, observational cohort studies assessing the safety and effectiveness of various interventions for people affected by bl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eaf2c0daed78a9a19548128bd94d1a42
https://doi.org/10.1182/blood-2021-148209
https://doi.org/10.1182/blood-2021-148209